Infectious Diseases

Top Medical News
Chronic Suppurative Otitis Media (luga)
15 hours ago
A recent systematic review and meta-analysis reveals a considerable burden of otitis media (OM) in China that is often overlooked. At present, the most common bacterial pathogen identified is Streptococcus pneumoniae (S pneumoniae).
What are the risk factors for severe infections in hospitalized SLE patients?
5 days ago
Among hospitalized patients with systemic lupus erythematosus (SLE), factors such as low immunoglobulin, anti-dsDNA antibody positivity, and cyclophosphamide use contribute to an increased risk of recurrent severe infections, according to a study.
MMF trumps azathioprine for remission in treatment-naive AIH
Stephen Padilla, 16 Apr 2024
Treatment with mycophenolate mofetil (MMF) in combination with prednisolone results in better biochemical remission rates at 24 weeks than the use of azathioprine plus prednisolone in patients with treatment-naïve autoimmune hepatitis (AIH), reports a study.
COVID rebound common, does not differ after VV116 vs nirmatrelvir–ritonavir treatment
Jairia Dela Cruz, 15 Apr 2024
Many patients with mild-to-moderate COVID-19 experience a resurgence of the virus as well as symptoms after a standard 5-day course of treatment with either VV116 or nirmatrelvir–ritonavir, as shown in a study from China.
Cancer survivors at risk of fractures
15 Apr 2024
Use of tenofovir disoproxil fumarate (TDF) for ≥24 months increases the risk of fracture in older patients with chronic hepatitis B (CHB), reports a study.
Probiotics may help in the fight against COVID-19
Audrey Abella, 15 Apr 2024
Post-exposure prophylaxis with the probiotic Lacticaseibacillus rhamnosus GG (LGG) led to prolonged time to COVID-19 infection, reduced incidence of symptoms, and gut microbiome changes, but not overall incidence, a study suggests.
2 drugs in 1 pill better than complex regimens for HIV
Elvira Manzano, 09 Apr 2024
The combination of bictegravir and lenacapavir, taken orally once daily, performed better than current complex treatment regimens in the phase II ARTISTRY-1 trial of people with HIV who are virologically suppressed.
Special Reports
Product Highlight - Spikevax XBB.1.5
21 Mar 2024
Andusomeran COVID-19 mRNA vaccine 50 mcg/dose
Long-acting antiretroviral therapy in holistic
management of an elderly patient with HIV
Dr. Thomas Shiu-Hong Chik, 14 Mar 2024
A 70-year-old female garment factory worker presented with an incidental finding of HIV infection following a diagnosis of pulmonary tuberculosis (PTB). She was screened positive after her partner received a diagnosis of HIV/PTB coinfection. 
COVID-19, nirmatrelvir, ritonavir, mRNA vaccine, Omicron, COPD, CDC, WHO
Dr. Chan Kwok Wai Adrian, Prof. Yang Kuang-Yao, 10 Jan 2024
At the 27th Congress of the Asian Pacific Society of Respirology (APSR) 2023, a Pfizer-sponsored symposium addressed the evolving challenges of COVID-19, particularly for patients with pre-existing respiratory conditions. Chaired by Dr Chan Kwok Wai Adrian, a renowned respiratory physician and intensivist from Mount Elizabeth Novena Hospital, Singapore, and featuring insights from Professor Yang Kuang-Yao of National Yang Ming Chiao Tung University, Taipei, Taiwan, the symposium focused on the disease’s impact, treatment guidelines, regional management strategies, and the role of nirmatrelvir/ritonavir, a new oral combination pill, in the treatment of COVID-19.
HCV pangenotypic DAA therapy in a patient with concomitant antipsychotic treatment
Dr. Ting-Ting Chan, 27 Oct 2023
A 43-year-old male former intra­venous drug user presented with in­cidental findings of elevated alanine transaminase (ALT) levels in Decem­ber 2021. The patient had depression and drug-induced psychosis associ­ated with previous heroin, ketamine and methamphetamine use. He was on quetiapine 300 mg daily for his psychotic symptoms, pantoprazole 40 mg daily as needed for occasional acid reflux, and simvastatin 10 mg dai­ly for hyperlipidaemia. He did not have hepatitis B virus (HBV) or human immunodeficiency virus (HIV) coinfection. 
HRQoL benefits and safety considerations with ART in people living with HIV
Mr. Nikos Dedes, Mr. Jeff Taylor, Ms. Bernadette Sharp, Dr. Iskandar Azwa, Dr. Dathan Byonanebye, Dr. Kristine Torjesen, 18 Oct 2023

Cabotegravir (CAB) plus rilpivirine (RPV) is a long-acting (LA) injectable antiretroviral therapy (ART) recommended for people living with HIV (PLHIV) who have achieved viral suppression with oral medications. The health-related quality of life (HRQoL) impact of injectable CAB + RPV (Vocabria®/ Rekambys®, GlaxoSmithKline) and safety considerations of ART were discussed by experts in public health and patient advocates in an industry-sponsored satellite symposium during the 12th International AIDS Society Conference on HIV Science (IAS 2023) held in Brisbane, Australia.

kidneys
18 Sep 2023
Remdesivir can be used in COVID-19 patients with severe renal impairment, including those on dialysis, according to recent US FDA approval of its expanded indication based on results of the REDPINE trial.
Management of severe COVID-19 in an elderly patient requiring supplemental oxygen
Dr. Shuk-Ying Chan, 18 Jul 2023
A 73-year-old male presented to the Accident & Emergency Department on 8 March 2022 (day 1) with fever (38°C), sore throat, cough, sputum and shortness of breath (SOB). Upon arrival, his blood pressure was 159/59 mm Hg, heart rate was 90 beats/minute, and oxygen saturation was 85 percent on room air, which improved to 96 percent with 3 L/min of supplemental oxygen. He was a hepatitis B virus carrier not receiving antivirals and had diabetes mellitus, which was well controlled with diet. He was not vaccinated against SARS-CoV-2 and had no prior exposure to COVID-19 oral antivirals.
Conference Reports
2 drugs in 1 pill better than complex regimens for HIV
Elvira Manzano, 09 Apr 2024
The combination of bictegravir and lenacapavir, taken orally once daily, performed better than current complex treatment regimens in the phase II ARTISTRY-1 trial of people with HIV who are virologically suppressed.
Intramuscular injection preferable to IV infusion of ibalizumab for PWH
Stephen Padilla, 22 Mar 2024
Ibalizumab delivered via intramuscular (IM) injection is not only safe and well-tolerated but also succeeds in viral suppression among heavily treatment experienced (HTE) people living with HIV (PWH), making IM the preferred method of administration among participants of the TMB-302 study.
Bulevirtide works well against chronic hepatitis D, HIV/HBV/HDV coinfection
Stephen Padilla, 21 Mar 2024
Patients with hepatitis delta virus (HDV) show increased virologic and biochemical responses with longer bulevirtide (BLV) treatment for over 96 weeks, with no new safety concerns, as shown in a study presented at CROI 2024.
High viral suppression feasible with BIC/FTC/TAF + rifampicin in adults with HIV, TB
Elaine Soliven, 19 Mar 2024

Twice-daily treatment with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) resulted in high viral suppression among people with HIV and tuberculosis (TB) who were on rifampicin-based therapy, according to the INSIGHT* trial presented at CROI 2024.

Injectable CAB/RPV superior to oral ART in ART-nonadherent people with HIV
Elaine Soliven, 16 Mar 2024

Treatment with cabotegravir and rilpivirine (CAB/RPV), a long-acting injectable antiretroviral therapy (ART), demonstrated superior efficacy in maintaining viral load suppression compared with oral standard of care (SoC) among people with HIV (PWH) who have difficulty adhering to ART, according to the ACTG A5359 LATITUDE* study presented at CROI 2024.

Is ART-free remission feasible in children born with HIV who received ART very early in life?
Audrey Abella, 13 Mar 2024
In the IMPAACT* P1115 study presented at CROI 2024, four children who received antiretroviral therapy (ART) for HIV very early in life remained free of detectable HIV for over a year after a break in their ART regimen.
Remdesivir may improve outcomes tied to long COVID
Audrey Abella, 12 Mar 2024
Remdesivir may cut the risk of symptoms and diagnoses associated with possible post-COVID conditions (PCC), otherwise known as long COVID.